<DOC>
	<DOC>NCT00812266</DOC>
	<brief_summary>Randomised trial comparing standard chemotherapy with carboplatin and etoposide with a combination of topotecan and cisplatin in patients with inoperable lung cancer of small cell type.</brief_summary>
	<brief_title>Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED)</brief_title>
	<detailed_description>Fase III, multicenter randomised trial comparing up to six cycles of carboplatin and etoposide with up to six cycles of topotecan and cisplatin in patients with extensive stage small cell lung cancer and PS 0-3</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Histologically confirmed SCLC Extensive stage No prior chemotherapy WHO PS 03 Adequate organ function (liver, kidney) Adequate hematology (bone marrow) Informed consent PS 4 Inadequate organ function Uncontrolled infection Concomitant major medical contraindications</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>SCLC</keyword>
	<keyword>Extensive disease</keyword>
	<keyword>topotecan</keyword>
</DOC>